Product Name: Blood Group Lewis y Antibody [A70-C/C8]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC-P
Applications: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 0.5-1 ug/mlImmunohistochemistry (FFPE): 0.5-1 ug/ml for 30 min at RTOptimal dilution of the Blood Group Lewis y antibody should be determined by the researcher.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Live Ls174T cells (human colon carcinoma) were used as the immunogen for the Blood Group Lewis y antibody.
Host Species: Mouse
Purification: PEG precipitation followed by dialysis in 1X PBS
Physical State: Liquid
CAS NO.: 2438-32-6
Product: Dexchlorpheniramine (maleate)
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names:
Accession NO.:
Protein Ino:
Official Symbol:
Geneid:
Background: This antibody recognizes a carbohydrate epitope common to the tumor-associated Lewis y and Lewis b antigens (Fucalpha1-2Galbeta1-4/3[Fucalpha1-3/4]GlcNAcbeta-). Its specificity was established without doubt with a panel of 86 synthetic mono- and oligosaccharidic structures. Lewis y is expressed in large bowel tumors and colorectal carcinomas. It may be useful in the classification of human renal and bladder tumors. The Lewis y antigen has been evaluated as a clinical marker for the diagnosis and prognosis of cholangiocarcinoma, hepatocellular carcinoma and breast cancer.
PubMed ID:http://aac.asm.org/content/42/3/545.abstract
